-
The crabs are drained of some of their blood and returned to the environment, yet some inevitably die. Regulators say revisions to guidelines for handling the animals should keep more alive through the process.
-
The company says its factory near Rocky Mount, North Carolina, makes nearly 25% of Pfizer's sterile injectable medicines used in U.S. hospitals
-
After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.
-
A quality-control crisis at an Indian pharmaceutical factory has left doctors and their patients with impossible choices as cheap, effective, generic cancer drugs go out of stock.
-
Victims of prescription opioid addiction as well as communities slammed by the opioid crisis could wind up with nothing if Mallinckrodt files for a second bankruptcy.
-
The drugmaker is seeking to halt the program, which was laid out in the Inflation Reduction Act and is expected to save taxpayers billions of dollars in the coming years.
-
Drug shortages continue as Florida health care experts navigate what some expect to be the new normal of pharmacy.
-
Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by President Donald Trump.
-
Drug shortages are growing in the United States, and experts see no clear path to resolving them. For patients, that could mean more treatment delays, medication switches and other hassles filling a prescription.
-
A group of former pro athletes traveled to Jamaica to try psychedelics as a way to help cope with the aftereffects of concussions and a career of body-pounding injuries. Will this still largely untested treatment work?